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Abstract
Vaccinia virus (VACV), the prototype poxvirus, encodes numerous proteins that modulate the host response to infection.
Two such proteins, B14 and A52, act inside infected cells to inhibit activation of NF-kB, thereby blocking the production of
pro-inflammatory cytokines. We have solved the crystal structures of A52 and B14 at 1.9 A ˚ and 2.7 A ˚ resolution, respectively.
Strikingly, both these proteins adopt a Bcl-2–like fold despite sharing no significant sequence similarity with other viral or
cellular Bcl-2–like proteins. Unlike cellular and viral Bcl-2–like proteins described previously, A52 and B14 lack a surface
groove for binding BH3 peptides from pro-apoptotic Bcl-2–like proteins and they do not modulate apoptosis. Structure-
based phylogenetic analysis of 32 cellular and viral Bcl-2–like protein structures reveals that A52 and B14 are more closely
related to each other and to VACV N1 and myxoma virus M11 than they are to other viral or cellular Bcl-2–like proteins. This
suggests that a progenitor poxvirus acquired a gene encoding a Bcl-2–like protein and, over the course of evolution, gene
duplication events have allowed the virus to exploit this Bcl-2 scaffold for interfering with distinct host signalling pathways.
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Introduction
Vaccinia virus (VACV), the smallpox vaccine, is the prototypic
member of the Poxviridae; a family of large, double-stranded DNA
viruses that replicate in the cytoplasm of host cells [1]. VACV strain
Copenhagen was the first poxvirus to be sequenced and encodes
about 200 genes [2]. The central portion of orthopoxvirus genomes
(,100 kb) is highly conserved and contains genes essential for virus
replication [3].Genes located towards the terminiare more variable
and, although non-essential for virus replication, they affect VACV
virulence, host range and modulation of the host immune system.
These VACV immunomodulators can act either inside or outside
infected cells [4]. Intracellular immunomodulators modulate
apoptosis, the anti-viral activity of interferons, innate immune
signalling and host gene transcription, whilst extracellular immu-
nomodulators inhibit the action of complement, interferons,
cytokines and chemokines [4–6].
Nuclear factor-kB (NF-kB) is a transcriptional complex that
plays a central role in stimulating innate and adaptive immune
responses to infection. Receptors for the pro-inflammatory
cytokines interleukin (IL)-1 and tumour necrosis factor alpha
(TNFa) activate signalling pathways leading to NF-kB activation
[7,8], as do Toll-like receptors (TLRs), which recognise pathogen-
associated molecular patterns such as in viral (glyco)proteins and
nucleic acids [9,10]. NF-kB activation downstream of the IL-1
receptor and TLRs requires TNF-receptor-associated factor 6
(TRAF6) and IL-1 receptor associated kinases (IRAKs), while
activation downstream of the TNF receptor requires TRAF2
[7,10]. These independent downstream signalling pathways
converge at the IkB kinase (IKK) complex, a key regulator of
signalling to NF-kB activation [7]. The importance of the immune
response initiated by proteins under NF-kB transcriptional
regulation upon virus infection is underscored by the fact that
VACV encodes several proteins, A52, A46, B14, K1, N1 and M2,
which interfere with the intracellular signalling pathways that lead
to the activation of NF-kB [11–16].
A52R is an immediate-early VACV gene [17] encoding a 23-
kDa intracellular protein (A52) that contributes to virus virulence
[16]. A52 functions by inhibiting NF-kB activation [14]
downstream of the IL-1 receptor and TLRs [18] via interactions
with IRAK2 and TRAF6 [16,18]. While the precise molecular
details of these interactions are unclear, the N-terminal death
domain of IRAK2 is essential for binding A52 [16], and a
truncation mutant of A52 lacking the C-terminal 46 residues
(A52DC46) retains the ability to both bind IRAK2 and inhibit NF-
kB activation [18,19]. Further, a peptide derived from A52 termed
PLoS Pathogens | www.plospathogens.org 1 August 2008 | Volume 4 | Issue 8 | e1000128‘P13’, comprising residues 125–135 of A52 plus a nine-arginine
cell-transducing sequence (which promotes cellular internalisation
of the peptide), inhibits TLR-mediated activation of NF-kB and
shows promise as a potent anti-inflammatory therapeutic [20]. In
addition to inhibiting NF-kB, A52 activates p38 MAP kinase and
enhances the TLR4-induced production of IL-10, a cytokine that
inhibits inflammatory and cell-mediated immune responses.
Activation of p38 MAP kinase is mediated by the direct binding
of A52 to the TRAF domain of TRAF6, and removal of the A52
C-terminal 46 residues abolishes the interaction with TRAF6 and
subsequent activation of p38 MAP kinase [16,19].
VACV strain Western Reserve gene B14R is an immediate-
early gene [17,21] that encodes a 17-kDa cytosolic protein (B14)
that contributes to VACV virulence [21] and inhibits the IKK
complex [13]. The interaction of B14 with the IKK complex
depends on the presence of IKKb, and B14 bound to the IKK
complex prevents phosphorylation of the IKKb activation loop.
Consequently, B14 inhibits the phosphorylation and subsequent
ubiquitin-mediated degradation of IkBa, the inhibitor of NF-kB
[13]. In this way, B14 blocks activation of NF-kB downstream of a
variety of stimuli including TNFa, IL-1, poly(I:C) and phorbol
myristate acetate [13].
While B14 and A52 share identifiable sequence similarity with
each other, being members of a Pfam [22] protein family that also
includes VACV proteins A46, K7, C6 and C16/B22, they do not
display significant sequence similarity to other cellular or viral
proteins [14,15,21,23]. Protein structure is more strongly con-
served during evolution than protein sequence [24] and
determination of virus protein structures is a powerful tool for
identifying previously undetermined functional and evolutionary
relationships [25]. For example, the recent crystal structures of
VACV N1 [26,27] and myxoma virus M11 [28,29] revealed that
these proteins possess Bcl-2–like structures despite sharing no
identifiable sequence similarity with the cellular Bcl-2 family of
proteins. Members of the Bcl-2 family are small a-helical proteins
that can be either pro- or anti-apoptotic and they regulate the
release of pro-apoptotic molecules from mitochondria [30]. The
structures of N1 and M11 both display conserved features
important for anti-apoptotic Bcl-2 function; namely the presence
of an elongated surface groove for binding a-helical motifs (BH3
peptides) of pro-apoptotic Bcl-2–like proteins and thereby
antagonizing their function. Functional studies performed in light
of these structure elucidations confirmed that N1 and M11 protect
cells from apoptosis by binding to pro-apoptotic Bcl-2 family
members such as Bid and Bax [26,29], the affinity [27,28] and
binding mode [29] being comparable to cellular anti-apoptotic
Bcl-2 family proteins. The structural and functional similarity of
the poxvirus and cellular Bcl-2–like proteins suggest that these
viral proteins had a cellular origin, a common theme in poxviruses
and other large DNA viruses [31–33].
To understand the mechanism of action and evolutionary
origins of VACV A52 and B14 in more detail, we have solved their
crystal structures at 1.9 A ˚ and 2.7 A ˚ resolution, respectively. We
show that both proteins are Bcl-2 family members but lack a
surface groove for binding BH3 peptides and, consonant with this,
are not anti-apoptotic. Instead these proteins have acquired the
ability to inhibit signalling pathways that activate NF-kB.
Results/Discussion
The structures of A52 and B14 were solved by multiple-
wavelength anomalous dispersion (MAD) experiments performed
upon crystals of selenomethionine (SeMet)-labelled protein
(Tables 1 & 2). The structures of two independent crystal forms
of an N-terminal truncated form of A52 comprising residues 37–
190 (A52DN36) were refined to 1.9 A ˚ and 2.8 A ˚ resolution with
residuals R/Rfree=0.177/0.215 and 0.181/0.192, respectively,
with residues 40–189 being observed in electron density maps in
both crystal forms (Figure 1A). Residue 190 and the first two
residues of the polyHis purification tag were also visible in the low-
resolution structure. Both crystal forms of A52 contain 2 molecules
per asymmetric unit arranged as a dimer, the overall fold
(0.3260.07 A ˚ root-mean-squared displacement [rmsd] over 150
C
a atoms) and dimer interface being highly conserved (Figure S1).
The structure of SeMet B14 was refined to 2.7 A ˚ resolution with
residuals R/Rfree=0.223/0.244, residues 8–149 being observed in
the electron density (Figure 1B). Four molecules of B14 are present
in the crystallographic asymmetric unit, forming two dimers with
highly conserved overall folds (0.1160.02 A ˚ rmsd over 142 C
a
atoms) and dimer interfaces (Figure S1).
The structures of A52 and B14 are entirely a helical, both
comprising seven a helices and adopting the Bcl-2–like fold
(Figure 1). The Bcl-2–like folds of A52 and B14 are surprising
given the low sequence similarity shared between A52, B14 and
other Bcl-2–like proteins (Table 3), and the structures contradict a
previous suggestion that A52 would adopt a fold like Toll-like–IL-
1 resistance (TIR) domains [14]. A structural similarity search
using SSM [34] identified the closest relative of both A52 and B14
to be N1 (Figure 1C), a VACV Bcl-2–like protein that inhibits
apoptosis [26,27] and which has also been reported to inhibit
signalling pathways leading to activation of NF-kB [35]. N1, A52
and B14 all homodimerise both in crystallo and in vitro (Figure S1,
[36] and data not shown). While the face of the structure involved
in dimerisation is generally conserved across these proteins, the
orientations of the two-fold rotation axes that relate the monomers
differ by up to 57u (Figure 2). Despite being a cytosolic protein,
and despite being purified and crystallised in the presence of the
reducing agent b-mercaptoethanol, a single disulphide bond is
observed in B14 between cysteine residues 15 and 46, locking the
N-terminal loop with the a1-a2 loop (Figure 1B). There is no
obvious functional role for this disulphide bond other than
stabilising the structure of the protein.
Author Summary
Cells possess formidable defences against virus infection,
but viruses have evolved sophisticated counter-measures
to evade such defences. Vaccinia virus, the vaccine used to
eradicate smallpox, has about 200 genes, and many of
these encode proteins that help the virus evade the host’s
immune defences. This paper concerns the vaccinia virus
proteins A52 and B14, which block signalling pathways
leading to the activation of the NF-kB transcription factor
and thereby diminish the host immune response to
infection. By solving the three-dimensional structures of
A52 and B14, we show that they closely resemble a family
of cellular and viral proteins (the Bcl-2 family) that usually
function to regulate apoptosis (a process by which cells
commit suicide, thereby stopping the replication of any
viruses with which they are infected). However, neither
A52 nor B14 regulate apoptosis. By comparing three-
dimensional structures, we show that vaccinia virus Bcl-2–
like proteins more closely resemble each other than they
do other cellular or viral Bcl-2–like proteins. This suggests
that an ancestor of vaccinia virus acquired a gene
encoding a Bcl-2–like protein from its host and, over time,
this gene has been copied and adapted for different
functions within the virus.
Evolution of Poxvirus Bcl-2–Like Proteins
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‘P13’ peptide sequence that in isolation can inhibit NF-kB
activation [20], form the surface loop between helices 4 and 5.
This is distal to the A52 dimerisation interface and is appreciably
different in length, amino acid composition and conformation to
the comparable loops in the other VACV Bcl-2–like proteins
(Figures 1 & 3). It is a likely candidate for mediating the interaction
with IRAK2, although such identification awaits direct experi-
mental confirmation. The final 46 residues, removed in the
A52DC46 truncation mutant that abolished TRAF6 binding and
the ability to stimulate p38 MAP kinase, comprise the final 6
residues of helix 5 and all of helices 6 and 7. Given that helices 5
and 6 contribute to the central core of the protein, it is unclear
whether this truncated protein would be stable and natively folded
(Figure 3) let alone whether it would dimerise like the native
protein (900 A ˚ 2 of the 1,300 A ˚ 2 of surface area buried by the
native dimer interface being abolished by the truncation). Further
study is therefore required to identify the binding face of TRAF6
on the surface of A52.
The determination of the structures of VACV proteins B14 and
A52 establishes that poxviruses encode a family of Bcl-2–like
proteins that also includes VACV N1 and myxoma virus M11.
These proteins have been reported to have diverse functions
including inhibition of apoptosis and interference with signalling
from several stimuli leading to activation of NF-kB. We therefore
undertook a direct comparison of the ability of these proteins to
inhibit apoptosis in response to staurosporine or inhibit NF-kB
activation in response to IL-1a or TNFa stimulation (Figure 4A) or
over-expression of TRAF2 or TRAF6 (Figure 4B). A52, B14 and
N1 all inhibit the activation of NF-kB to some degree in response
to IL-1a or downstream of TRAF6. However, only B14 is able to
block signalling downstream of TNFa/TRAF2. This is due to the
ability of B14 to inhibit signalling from the IKK complex via its
interaction with IKKb: the nexus where IL-1 receptor, TNF
receptor and TLR signalling pathways to NF-kB converge [13].
The ability of A52 to inhibit IL-1a– but not TNFa–induced
signalling is consistent with previous findings [14,16], whereas the
inability of N1 to inhibit TNFa signalling is inconsistent with a
prior report [35]. The mechanism by which N1 inhibits signalling
downstream of IL-1a is unclear. However, given that N1 inhibits
TRAF6-induced NF-kB activation but does not interact with the
IKK complex [13], contrary to previous suggestions [35], it is
likely that it acts at the level of TRAF6 or on downstream proteins
in the pathway that precede the IKK complex. M11 did not
inhibit either pathway, consistent with a primarily anti-apoptotic
function during virus infection [29]. To test whether the N
terminus of A52, predicted to be unstructured and removed for
crystallisation, is required for anti–NF-kB activity, full length A52
and the A52DN36 truncation were compared for their ability to
block signalling induced by IL-1a (Figure 4C). A52DN36 had a
comparable inhibitory effect to the full-length protein, indicating
that the N-terminal 36 residues are not necessary for the inhibitory
action of A52.
Anti-apoptotic Bcl-2–like proteins inhibit apoptosis by binding
the BH3 peptides of pro-apoptotic Bcl-2–like and BH3-only
proteins in a hydrophobic groove on the surface of the anti-
apoptotic protein [30]. While both N1 and M11 block
mitochondrial apoptosis in cells treated with the pan-kinase
inhibitor staurosporine (Figures 5A & S2), consistent with previous
reports [26,29], neither B14 nor A52 block apoptosis (Figures 5A
& S2). Superposition of our structures onto that of myxoma virus
M11 in complex with the BH3 peptide of Bak [29] reveals the
hydrophobic BH3-peptide binding grooves are occluded in both
A52 and B14, but not in N1 (Figure 5). Residues 92–94 and 117–
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PLoS Pathogens | www.plospathogens.org 3 August 2008 | Volume 4 | Issue 8 | e1000128122 block the groove in A52, the C-terminal ends of helices 2 and
4 being oriented closer to each other than in M11, thereby
narrowing the groove significantly, and the side chains of Q93,
F94 and Y118 pointing directly into and filling the groove.
Equivalent residues (63–66 and 82–90) occlude the groove of B14,
helices 2 and 4 again being much closer to each other than in M11
and three side chains (V64, F65 and Y90) pointing directly into
and blocking the groove. Bcl- xL and BHRF1, two Bcl-2 family
proteins that are able to bind BH3 peptides and thereby inhibit
apoptosis, have restricted grooves that are ‘closed’ in the absence
of bound BH3 peptide [37–39]. Movement of helices 3 and 4
widens the Bcl-xL groove to allow BH3-peptide binding [39] and,
while a structure of BHRF1 in complex with a BH3 peptide is not
available, it is likely that rearrangement of the loop between
helices 4 and 5 would be required for BH3-peptide binding. In
contrast, blockage of the BH3-peptide binding groove by residues
Table 2. Refinement statistics.
High resolution A52 Low resolution A52 B14
Space group P21 R3:H C2
Resolution limits (A ˚)
a 33.8–1.9 (1.95–1.90) 40.1–2.8 (2.89–2.75) 46.3–2.7 (2.76–2.70)
Reflections in working set
a 29,385 (2,161) 19,183 (2,611) 36,439 (2,577)
Reflections in test set
a 1,571 (86) 988 (135) 1,783 (99)
R factor of working set
a, b 0.177 (0.252) 0.181 (0.287) 0.223 (0.381)
Rfree (%)
a, b, c 0.215 (0.298) 0.192 (0.302) 0.244 (0.412)
Number of atoms (protein/water) 2,508/207 2,516/0 4,632/0
Number of atoms with alternate conformations (protein/water) 36/0 12/– 0/–
Residues in Ramachandran favoured region (%) 99.3 98.0 97.7
Ramachandran outliers (%) 0.0 0.0 1.4
rmsd bond lengths (A ˚) 0.010 0.005 0.005
rmsd bond angles (u) 1.107 0.816 0.777
Average B factors (A ˚2) (protein/water) 29.6/38.0 81.7/– 62.5/–
aNumbers in parentheses are for the highest resolution shell.
bR=ShklIFobs(hkl)|2|Fcalc(hkl)I/Shkl |Fobs(hkl)|, where |Fobs(hkl)|a n d| Fcalc(hkl)| are the observed and calculated structure facture amplitudes.
cRfree equals the R-factor of test set (5% of the data removed prior to refinement).
doi:10.1371/journal.ppat.1000128.t002
Figure 1. Vaccinia virus (VACV) proteins A52 and B14 share a Bcl-2–like fold. (A) A52 and (B) B14 are shown as ribbons, ramp coloured from
blue (N terminus) to red (C terminus). The disulphide bond observed in B14 is shown as purple spheres. (C) The structure of the poxvirus Bcl-2–like
protein N1 (cyan; PDB ID 2uxe). (D) Structure-based sequence alignment of the VACV Bcl-2–like proteins. Residues that are highly or moderately
conserved (BLOSUM62 score) are coloured marine and light blue, respectively, and cysteine residues that form the disulphide bond observed in B14
are boxed and in purple face. Residues of A52 that encompass the ‘P13’ peptide and residues removed in the A52DC46 mutant, which does not bind
TRAF6, are marked with a solid and a dashed line, respectively. The secondary structures of A52, B14 and N1 are shown above the sequences with a
helices represented as cylinders.
doi:10.1371/journal.ppat.1000128.g001
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PLoS Pathogens | www.plospathogens.org 4 August 2008 | Volume 4 | Issue 8 | e1000128at the C-terminal end of helix 2 is characteristic of A52 and B14
(Figure 5D) and we propose that it explains the inability of A52
and B14 to protect cells from apoptotic challenge. Interestingly,
helix 2 of N1 has the same orientation as in A52 and B14 but is
one turn shorter and thus doesn’t occlude the BH3-peptide–
binding groove (Figure 5D). This is consistent with both the ability
Table 3. Structural and sequence similarity of poxvirus, herpesvirus and cellular Bcl-2–like proteins.
VACV A52
(2vvw)
VACV B14
(2vvy)
VACV N1
(2i39)
Myxoma virus
M11 (2jbx)
Murine gamma-herpesvirus
68 Bcl-2 like (3bl2)
Mouse Bcl-xL
(2bzw)
Human Bid
(2bid)
VACV A52 (2vvw) – 1.91 (124) 1.96 (108) 2.46 (107) 2.49 (100) 2.72 (111) 2.84 (91)
VACV B14 (2vvy) 21.8 – 2.33 (101) 2.46 (95) 2.55 (105) 2.79 (103) 2.51 (89)
VACV N1 (2i39) 18.5 15.8 – 2.29 (101) 2.36 (97) 2.75 (103) 2.83 (84)
Myxoma virus M11 (2jbx) 11.2 5.3 9.9 – 2.38 (105) 2.33 (109) 2.90 (83)
Murine gamma-herpesvirus
68 Bcl-2 like (3bl2)
5.0 11.4 14.4 5.7 – 2.26 (112) 3.13 (95)
Mouse Bcl-xL (2bzw) 3.6 8.7 8.7 11.0 20.5 – 2.84 (105)
Human Bid (2bid) 6.6 6.7 13.1 9.6 10.5 10.5 –
PDB IDs for the structures used in the comparisons are shown in parentheses. C
a rmsds and numbers of equivalent residues (in parentheses) are shown above the
diagonal, sequence identities of equivalent residues (%) are shown below.
doi:10.1371/journal.ppat.1000128.t003
Figure 2. A52, B14 and N1 utilise a conserved face for dimerisation, but the 2-fold rotations that relate monomers of the dimers
differ significantly. (A) Superposition of A52 (orange), B14 (magenta) and N1 (cyan; PDB ID 2uxe). (B–D) The molecular surfaces of (B) A52, (C) B14
and (D) N1 are shown in white, residues that form intermolecular (dimer) contacts being coloured orange (A52), magenta (B14) or cyan (N1). The
molecules are oriented as in (A). Cylinders represent the two-fold rotation axes of the respective dimers.
doi:10.1371/journal.ppat.1000128.g002
Figure 3. Regions of A52 implicated in TRAF6 and IRAK2 interactions. The A52 dimer is shown in ribbon representation with residues that
encompass the ‘P13’ peptide (residues 125–135) coloured orange and residues removed in the A52DC46 mutant (residues 145–189) coloured blue.
While the putative IRAK2-interacting loop is exposed on the surface of A52, residues 145–189 form part of the core of the protein. (Left inset) The
molecular surface of A52DC46 is shown in white, with A52 residues removed in this mutant (residues 145–189) shown as a blue ribbon. (Right inset)
The structures of A52, B14 and N1 are shown superposed. Thicker coloured tubes denote the regions equivalent to residues 125–135, encompassing
the ‘P13’ peptide, of A52 (orange): B14 residues 89–102 (magenta) and N1 residues 63–70 (cyan).
doi:10.1371/journal.ppat.1000128.g003
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is an evolutionary ‘intermediate’ between the apoptosis-regulating
Bcl-2–like proteins and those that inhibit NF-kB activation.
To investigate the evolutionary relationship between A52, B14, N1
and other Bcl-2–like proteins further, a structure-based phylogenetic
tree [25] was calculated using all-pairs pairwise structural superpo-
sitions of A52, B14 and 30 representative cellular and viral Bcl-2–like
proteins (Figure 6). Amongst the cellular Bcl-2–like proteins,
orthologues are seen to cluster together, residing closer to each other
o nt h et r e et h a nt op a r a l o g u es t r u c t u r e sf r o mt h es a m es p e c i e s .
However, the poxvirus Bcl-2–like proteins are allmore similar to each
other than they are to cellular Bcl-2–like proteins despite their
Figure 4. The relative effects of A52, B14, N1 and M11 on signalling to NF-kB. (A) VACV Bcl-2–like proteins affect signalling to NF-kB
downstream of IL-1a and TNFa differently. HEK 293 cells were transfected with FLAG-tagged expression alleles for A52, B14, N1, M11 or empty vector
(pCI; EV) together with an NF-kB reporter plasmid and Renilla internal control. Cells were treated with 100 ng/ml of IL-1a, TNFa or left untreated for
8 h, lysed and assayed for NF-kB–inducible luciferase activity. (B) B14, but not A52, blocks activation of NF-kB downstream of TRAF2 and TRAF6. HEK
293 cells were transfected with FLAG-tagged expression alleles for A52, B14, N1, M11 or empty vector (pCI; EV) together with plasmids for NF-kB
reporter gene, Renilla internal control and either TRAF2 or TRAF6. Cells were lysed 24 h post-transfection and measured for NF-kB–inducible
luciferase activity. (C) The N terminus of A52 is not required for inhibition of NF-kB downstream of IL-1a. HEK 293 cells were transfected with pOPINE
vectors containing C-terminally His-tagged full length A52 or C-terminally His-tagged A52 lacking residues 1–36 (A52DN36), FLAG-tagged B14 or
empty vector (pOPINE; EV) together with NF-kB reporter and Renilla internal control. Cells were treated as in (A). Data are expressed as
means6standard deviation of 2–4 independent experiments. Statistics: two-tailed Student’s t-Test (*P,0.05, **P,0.005 ***P,0.0005).
doi:10.1371/journal.ppat.1000128.g004
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like proteins are the proteins from gamma herpes viruses (EBV,
KSHV and MHV-68) and M11. These proteins bind pro-apoptotic
BH3-peptides and are potent inhibitors of apoptosis
[28,29,37,38,40,41]. More distantly related is N1, which both inhibits
apoptosis by binding BH3-peptides and interferes with NF-kB
activation (Figures 4 & 5). The proteins most distinct from cellular
Bcl-2–like proteins, A52 and B14, lack a BH3-peptide binding groove
and inhibit NF-kB activation rather than apoptosis (Figure 5). This is
consistent with the hypothesis that an ancestral poxvirus acquired a
gene encoding a Bcl-2–like protein from its host and over evolution
this useful protein scaffold has been adapted to interfere with several
different cellular signalling pathways [31–33]. As poxvirus and
cellular Bcl-2–like proteins are of a similar size, convergence of
separately-acquired cellular Bcl-2–like proteins to this common,
minimal fold in the virus seems unlikely. Interestingly, the poxvirus
Bcl-2–like proteins are more closely related to Bcl-2–like proteins
from herpes viruses than they are to cellular Bcl-2–like proteins. This
might imply either some elements of common ancestry of poxviruses
and herpes viruses, independent acquisition of the same cellular Bcl-
2–like protein by both virus families, or horizontal gene transfer
between the viruses. While Bid lies closer to viral than cellular Bcl-2–
like proteins, it is only distantly related to either group (Tables 3 &
S1). Its position in the tree most likely arises from a form of ‘long-
branch attraction’ [42] and does not reflect a close evolutionary
relationship with viral Bcl-2–like proteins.
We have now shown that three VACV proteins, N1, A52 and
B14, all adopt the Bcl-2–like fold despite sharing little sequence
identity and having different functions. A52 and B14 are both
members of a protein family (PF06225) that also includes VACV
proteins A46 (VACWR172), C6 (VACWR022), C16/B22 and K7
(VACWR039) (Figure S3) [14,23] and it is likely that these proteins
will also adopt a Bcl-2–like fold. Like B14 and A52, A46 inhibits
activation of NF-kB, although it does so by an independent
mechanism, binding directly to the TIR domains of TLR4 and of
the TLR-associated proteins MyD88, TRIF, TRAM and Mal
[14,15]. The sequence similarity shared between A52, B14 and A46
make it likely that A46 will share the Bcl-2 fold, rather than the TIR
fold as suggested previously [15]. The functions of C6, C16/B22
andK7areunknown,althoughpeptides derived from C6and C16/
B22 are presented to CD8
+ cells by MHC-I during VACV
infection, confirming that these proteins are expressed [43,44].
[Note that C16/B22 is distinct from the vaccinia serpin-like serine
protease inhibitor SPI-1 (also known as B22)] [45,46]. Temporal
profiling of VACV gene expression during infection shows A52,
B14,C6and K7tobeimmediate-earlygenesand A46 tobeanearly
Figure 5. A52 and B14 lack a surface BH3-peptide binding groove and do not block apoptosis. (A) HeLa cells were transfected with
vectors expressing FLAG-tagged A52, B14, N1, M11, untagged Bcl-xL or empty control vector (pCI; EV) together with CD20 expression vector. After a
further 24 h, cells were treated with 0.5 mM staurosporine for 1 h or left untreated and assayed for mitochondrial dysfunction by JC-1 staining and
FACS analysis. Data are expressed as means6standard deviation of 3 independent experiments. Statistics: two-tailed Student’s t-Test (*P,0.05,
**P,0.005). (B and C) The BH3-peptide binding groove of M11 is occluded in both A52 and B14. The structures of (B) A52 (orange ribbon) and (C) B14
(magenta ribbon) are shown superposed upon the structure of myxoma virus M11 (light grey ribbon) in complex with the BH3 peptide of human
Bak-2 (lime green helix; PDB ID 2jby). Side chains that block the BH3-peptide binding groove are shown as sticks. (D) Stereogram depicting
superposed C
a traces of A52 (orange), B14 (magenta), VACV N1 (cyan; PDB ID 2uxe), myxoma virus M11 (light grey; PDB IDs 2jbx and 2jby), mouse Bcl-
xL (yellow; PDB IDs 1pq0 and 1pq1) and Epstein-Barr virus BHRF1 (dark blue; PDB ID 1q59). Two conformations of M11 and Bcl-xL are shown (in the
presence and absence of bound BH3 peptide). The BH3 peptide of human Bak-2 in complex with myxoma virus M11 is shown (lime green helix; PDB
ID 2jby).
doi:10.1371/journal.ppat.1000128.g005
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during infection are often associated with modulation of the host
immune response [1,17]. Therefore, immediately after or early
during infection poxviruses express a number of proteins that adopt
the Bcl-2–like fold. While the precise roles of C6, K7 and C16/B22
remain to be determined, it is evident that poxviruses have adapted
the Bcl-2–like fold to interfere at multiple points along signalling
pathways mediating the host immune response to viral infection.
In summary, we have solved the structure of the VACV
immunomodulatory proteins A52 and B14. These proteins both
adopt the Bcl-2–like fold, despite sharing little sequence identity with
v i r a lo rc e l l u l a rB c l - 2 – l i k ep r o t e i n s .N e i t h e rA 5 2n o rB 1 4i n h i b i t
apoptosis as they lack a hydrophobic surface groove capable of
binding pro-apoptotic BH3 peptides. Further, A52 and B14 are
representative members of a protein family that also includes VACV
proteins K7, C6, A46 and C16/B22, and it is likely that all these
proteins will adopt a Bcl-2–like fold despite their varied functions.
Structure-based phylogenetic analysis of viral and cellular Bcl-2–like
proteins reveal that poxvirus Bcl-2–like proteins are more similar to
each other than they are to cellular Bcl-2–like proteins, implying that
these poxvirus Bcl-2–like proteins share a common evolutionary
origin.
Materials and Methods
Expression plasmids
Full-length A52 and an N-terminal truncation lacking residues 1–
36 (A52DN36) were amplified from VACV Western Reserve (WR)
cDNA using KOD HiFi DNA polymerase (Novagen) according to
the manufacturer’s instructions (forward primer: 59- AGGAGATA-
TACCATGGACATAAAGATAGATATTAGTATTTCTGG-39,
reverse primer: 59-GTGATGGTGATGTTTTGACATTTCCA-
CATATACTAGTCTATTC-39 [A52] and forward primer: 59-
AGGAGATATACCATGACTGATGTTATCAAACCTGATTA-
TCT-39, reverse primer: 59-GTGATGGTGATGTTTTGA-
CATTTCCACATATACTAGTCTATTC-39 [A52DN36]). The
genes were cloned into pOPINE (adding a C-terminal Lys-His6
fusion tag) by InFusion cloning [47]. Full-length B14 (residues 1–149)
wasamplified by PCRfrom VACV WR cDNA using HiFi Taq DNA
polymerase (Geneaid) with primers containing NdeI and EcoRI
Figure 6. Structure-based phylogenetic analysis of virus and cellular Bcl-2–like proteins. The structures were superposed and a pairwise
distance matrix was constructed as described in Materials and Methods. PDB codes for each structure used are given followed by their species of
origin in parentheses [Human (H), Mouse (M), Rat (R), C. elegans (C), Vaccinia virus (VACV), Myxoma virus (MV), Kaposi sarcoma herpes virus (KSHV),
murine gamma-herpesvirus 68 (MHV), Epstein-Barr virus (EBV)]. Structures determined by X-ray crystallography are labelled in black, NMR models in
grey and structures of Bcl-2–like proteins in complex with BH3 peptides are italicised. It is not certain that all Bcl-2–like proteins share a common
ancestor and, as such, the root of the tree is shaded. Ribbon diagrams of representative structures for each protein are colour ramped from blue (N
terminus) to red (C terminus).
doi:10.1371/journal.ppat.1000128.g006
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TATGACGGCCAACTTTAGTACC-39, reverse primer: 59-
CTCGAATTCTCATCAATTCATACGCCGGAA-39; sequences
encoding restriction sites are underlined). The PCR product was
cloned into pET28a (Promega) cut with NdeI and EcoRI (Roche)
using T4 DNA ligase (Promega), the resultant plasmid encoding full-
l e n g t hB 1 4w i t ha nN - t e r m i n a lH i s 6 fusion tag.
pCI-based expression plasmids for FLAG-tagged N1 and B14
were constructed as described previously [13,26]. Plasmids
containing FLAG-tagged A52, TRAF2, TRAF6, NF-kB luciferase
reporter and pTK-Renilla luciferase internal control were gifts from
Dr. Andrew Bowie (Trinity College, Dublin, Ireland). FLAG-
tagged M11 was a gift from Dr. David Huang (The Walter and
Eliza Hall Institute of Medical Research, Melbourne, Australia)
and Bcl-xL was provided by Professor Xin Lu (Ludwig Institute for
Cancer Research, London, United Kingdom). Relative protein
expression levels were verified by immunoblotting using anti-
FLAG or anti-Bcl-xL monoclonal antibodies.
Large-scale expression
Both unlabelled and selenomethionine (SeMet)-labelled
A52DN36 were overexpressed by autoinduction in E. coli Rosetta
(DE3)pLysS cells [48] and stored frozen (280uC) until required.
The final mass obtained for cells expressing SeMet-labelled
A52DN36 (0.5 g/L) was much lower than obtained for those
expressing the unlabelled protein (,10 g/L). SeMet-labelled B14
was expressed in E. coli B834(DE3) cells (grown in the presence of
30 mg/mL kanamycin) using SeMet medium (Molecular Dimen-
sions) supplemented with 40 mg/L L-SeMet. Cultures were grown
at 37uC to an optical density (OD600) of 0.6, cooled to 20uC and
protein expression was induced by the addition of 1 mM isopropyl
b-D-thiogalactopyranoside. Cells were harvested after 16 h
incubation by centrifugation (5,500 g,4 uC, 20 min) and the cell
pellet was stored frozen (280uC) until required.
Purification of A52DN36
Thawed cells were resuspended in 50 mM Tris pH 7.5,
500 mM NaCl, 20 mM imidazole, 0.2% v/v TWEEN-20,
supplemented with ,5 mg hen egg-white lysozyme (Sigma) and
1 EDTA-free protease inhibitor tablet (Roche), and incubated for
1 h at 20uC before being sonicated on ice for 5 min until the cells
were lysed completely. The cell lysate was cleared by centrifuga-
tion (45,000 g,8 uC, 30 min) and incubated with 1–2 mL of Ni
Sepharose 6 Fast Flow beads (GE Healthcare) for 1 h at 4uC
before being loaded into a disposable chromatography column
(BioRad). Beads were washed with 15 c.v. of 50 mM Tris pH 7.5,
500 mM NaCl, 20–40 mM imidazole and the protein was eluted
in 50 mM Tris pH 7.5, 500 mM NaCl, 500 mM imidazole.
Pooled fractions containing A52DN36 were diluted 10-fold in gel-
filtration buffer (20 mM Tris-HCl pH 7.5, 200 mM NaCl),
concentrated and then applied to a Superdex 75 column (GE
Healthcare) equilibrated in gel-filtration buffer. SDS-PAGE
confirmed the purity (.98%) of the protein and mass-spectrom-
etry confirmed both the identity of native A52DN36 and the
percentage Se incorporation (100%) of the SeMet-labelled protein
(data not shown).
Purification of B14
Cells were thawed, resuspended in 50 mM Tris pH 8.0,
500 mM NaCl, 1 M non-detergent sulphobetaine 201, 2% v/v
Triton X-100 and 2 mM b-mercaptoethanol, cooled on ice and
sonicated until the cells were lysed completely. Lysate was cleared
by centrifugation (20,000 g,4 uC, 30 min) and applied to a 5 mL
Ni-Sepharose HiTrap affinity chromatography column (GE
Healthcare) that had been equilibrated in binding buffer
(30 mM imidazole, 500 mM NaCl, 20 mM Tris pH 7.9, 2 mM
b-mercaptoethanol). The column was washed with binding buffer
(5 c.v.) and eluted with an increasing gradient of imidazole (30–
500 mM). Fractions containing B14 were pooled and applied to a
Superdex 75 column (GE Healthcare) equilibrated in 50 mM
Tris-HCl pH 8.5, 150 mM NaCl, 2 mM b-mercaptoethanol.
SDS-PAGE and mass-spectrometry confirmed the purity (.98%)
and identity of the purified protein (data not shown). The presence
of b-mercaptoethanol throughout the purification was essential to
prevent aggregation and precipitation of the protein.
Crystallisation and data collection
Purified A52DN36 and B14 were concentrated to 5.2–5.4 mg/
mL and 3.2 mg/mL in 5 kDa MWCO (Vivascience) and 10 kDa
MWCO (Millipore) microconcentrators, respectively. Initial
screening of crystallisation conditions was performed at 21uCi n
96-well plates with sitting drops (100 nL protein+100 nL reservoir)
equilibrated against 95 mL of reservoir solution [49]. For
unlabelled and SeMet-labelled A52DN36, initial crystallisation
conditions were scaled up as hanging drops (1 mL protein+1 mL
reservoir) in 24-well Linbro-style plates equilibrated at 21uC
against 500 mL reservoirs containing 15–21% w/v polyethylene
glycol 3350 and 0.2–0.24 M tri-sodium citrate (space group P21)
or 22% w/v polyethylene glycol 3350 and 0.2 M sodium
phosphate (space group R3), diffraction quality crystals appearing
within 48 h. For B14, initial crystallisation conditions were
optimized by screening additives [49] and diffraction quality
crystals were obtained in 48 h against reservoirs containing 0.2 M
di-ammonium tartrate, 20% w/v polyethylene glycol 3350, 0.4 M
non-detergent sulphobetaine 201 and 2 mM b-mercaptoethanol.
All crystals were cryoprotected by a quick pass through reservoir
solution supplemented with 20% v/v glycerol before being flash-
cryocooled in a cold (100 K) stream of N2 gas.Diffraction data were
collected at 100 K at the ESRF beamlines ID14-4 (high resolution
unlabelled A52) and BM14 (SeMet-lebelled B14 and A52) and at
Diamond beamline I03 (low resolution unlabelled A52). Diffraction
data were processed with HKL2000 [50] (Table 1).
Structure solution, refinement and validation
The three wavelengths of the A52 MAD experiment were cross-
scaled, the selenium sites were located, the selenium substructure
was refined, and calculated phases were solvent-flattened with
SHELXD [51], SHARP [52], DM [53] and SOLOMON [54] as
implemented by the AutoSHARP structure solution pipeline [55].
The chain was traced using ARP/wARP [56], 281 of the 304
residues in the final model being positioned automatically. For all
structures, manual model manipulation was performed using
COOT [57]. For B14, the three wavelengths of the MAD
experiment were cross-scaled and selenium sites were located using
SHELXC and SHELXD as implemented in HKL2MAP [58].
Initial phases were calculated using SHARP [59], solvent
flattening was performed using RESOLVE [60], and the
backbone was traced manually.
Initial structure refinement was performed using CNS [61]
(B14) or using REFMAC5 with phase restraints [62] (A52). The
high-resolution structure of unlabelled A52 (space group P21) was
determined directly from the isomorphous structure solved by
MAD analysis and the lower-resolution (R3) structure by
molecular replacement using PHASER [63]. Final refinement
was performed using REFMAC5 (high resolution A52) or
phenix.refine [64] (B14 and low-resolution A52) in consultation
with the validation tools present in COOT and the MolProbity
web server [57,65]. For B14 and the low-resolution structure of
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out the refinement. Atomic coordinates and structure factors have
been deposited with the Protein Data Bank, accession IDs 2vvw
(high-resolution A52), 2vvx (low-resolution A52) and 2vvy (B14).
Structural analysis
The representative set of Bcl-2–like structures used for structure-
based phylogenetic analysis were selected with the assistance of the
SSM web server [34]. Gap-penalty–weighted pairwise superposi-
tion of all Bcl-2–like structures was performed using the program
SHP [66] to maximise the sum of probabilities of equivalence
between pairs of residues for the proteins being compared [67].
The total summed probability was converted into an estimate of
the evolutionary distance using the expression: D=2log[(P-2)/
(,N.-2)], where D is the evolutionary distance, P is the sum of
probabilities and ,N. is the mean number of residues in the two
molecules [25]. For crystal structures where more than two Bcl-2–
like molecules were present in the asymmetric unit the most
representative monomers as determined using the MCentral
command of LSQMAN [68] was used for the analysis. For
structures with two Bcl-2–like molecules per asymmetric unit
‘chain A’ was chosen arbitrarily. For NMR ensembles, the ‘core’ of
the most representative member of the ensemble as determined by
the OLDERADO server [69] was used. The tree representation
was generated from the matrix of evolutionary distances using the
programs FITCH and DRAWTREE, part of the PHYLIP
package [70], using default parameters. C
a rmsds, numbers of
equivalent residues and evolutionary distances used to generate the
phylogenetic tree are presented in Table S1.
Structure-based multiple sequence alignments were generated
from superposed co-ordinate files (see above) with the ‘‘Match-
.Align’’ tool in UCSF Chimera [71] using default parameters.
InteractioninterfaceswereanalysedusingthePISA webserver[72].
Reporter assays
Human embryonic kidney 293 (HEK 293) cells (1610
5 per well)
were seeded in 24-well plates and transfected with 250 ng of
expression plasmid encoding either FLAG-tagged A52, B14, N1,
or M11, together with 100 ng of NF-kB-luc reporter plasmid and
10 ng of pTK-Renilla luciferase internal control with FugeneHD
(Roche) according to the manufacturer’s instructions. For analysis
of the function of the N terminus of A52, cells were transfected
with pOPINE vectors expressing either C-terminally His-tagged
full-length A52 or A52DN36 (described above), together with
plasmids encoding the NF-kB reporter and Renilla internal control.
The total amount of DNA (500 ng) was kept constant by
supplementation with pCI (Promega) or pOPINE. After overnight
incubation, the transfected cells were simulated with 100 ng/ml of
IL-1a or TNFa (Peprotech) for 8 h. Alternatively, cells were
transfected with 200 ng of the A52, B14, N1, or M11 expression
alleles together with 190 ng TRAF2 or TRAF6, 100 ng of NF-kB-
luc reporter plasmid and 10 ng of pTK-Renilla luciferase internal
control and were incubated for 24 h. Cells were harvested in
passive lysis buffer (Promega), and the relative stimulation of NF-
kB activity was calculated by normalizing luciferase activity with
Renilla luciferase intensity. In all cases, data shown are from one of
two to four independent experiments with similar qualitative
results. Data from experiments performed in triplicate are
expressed as means6standard deviation.
Apoptosis assay
Apoptosis was measured as described previously [26]. Briefly,
HeLa cells were transfected with expression vectors for FLAG-
tagged A52, B14, N1, M11, untagged Bcl-xL or empty vector (pCI)
together with a CD20 surface transfection marker using
FugeneHD (Roche). Cells were stimulated with 0.5–1 mM
staurosporine for 1 h or left untreated as indicated. The level of
apoptosis was assessed by measuring the change in mitochondrial
potential (Dym) using the potentiometric dye JC-1. Cells were
collected, washed in phosphate-buffered saline (10 mM phosphate
pH 7.4, 137 mM NaCl; PBS) and stained with anti-CD20 APC
antibody (BD Pharmingen) for 20 min on ice. Cells were then
stained with 2 mM JC-1 dye (Invitrogen) for 30 min at 37 uC,
washed in PBS, re-suspended in FACS buffer (PBS with 2% v/v
foetal calf serum) and analyzed by flow cytometry (FACScan;
Becton Dickinson). Data was analysed using Summit software
(Dako). To assess relative protein expression levels, cells remaining
after FACS analysis were collected and harvested in RIPA buffer
[50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton v/v X-100,
1% w/v sodium deoxycholate and 0.1% w/v SDS with protease
inhibitor cocktail tablets (Roche)]. Lysates were separated by SDS-
PAGE (15% gel), transferred to nitrocellulose membranes and
blotted for the presence of N1, A52, B14, M11 using anti-FLAG
monoclonal antibody (Sigma) or for Bcl-xL using an anti-Bcl-xL
monoclonal antibody (Cell Signalling Technologies). Equal protein
loading was assessed using an anti-tubulin-a polyclonal antibody
(Chemicon).
Supporting Information
Figure S1 A52 and B14 are dimers. (A) Overlay of the structures
of A52 solved in space groups P21 (orange) and R3 (green). (B)
Overlay of the two dimers of B14 present in the asymmetric unit
coloured green and magenta, respectively.
Found at: doi:10.1371/journal.ppat.1000128.s001 (3.51 MB TIF)
Figure S2 Unlike N1, M11 and Bcl-xL, A52 and B14 do not
inhibit apoptosis. (A) HeLa cells were transfected with vectors
expressing FLAG-tagged A52, B14, N1, M11, untagged Bcl-xL or
empty control vector (pCI; EV) together with CD20 cell-surface
expression vector. After a further 24 h, cells were treated with
1 mM staurosporine for 1 h or left untreated and assayed for
mitochondrial dysfunction by JC-1 staining and FACS analysis.
Data are expressed as means6standard deviation of 2–4
independent experiments. Statistics: two-tailed Student’s t-Test
(*P,0.05, **P,0.005, ***P,0.0005). (B) Cells used for FACS
analysis in (A) were harvested, normalised for protein content,
separated by SDS-PAGE and immunoblotted for N1, B14, A52
and M11 using an anti-FLAG antibody or Bcl-xL using an anti-
Bcl-xL antibody. Equal loading is shown by immunoblotting with
an anti-tubulin-a antibody.
Found at: doi:10.1371/journal.ppat.1000128.s002 (0.42 MB TIF)
Figure S3 Multiple sequence alignment of the VACV A52/B14
family of proteins. The alignment shown is based on the Pfam [22]
alignment, modified to maximise structural equivalences between
A52 and B14 (see Figure 1D). Sequences are from VACV WR for
all proteins except C16/B22, which is from VACV Copenhagen,
and UniProt accession IDs are shown in parentheses. Residues
that are highly or moderately conserved (BLOSUM62 score) are
coloured marine and light blue, respectively. The secondary
structures of A52 and B14 are shown above the sequences with a
helices represented as cylinders. A graph of the conservation score
for each residue [73] is shown beneath the sequences.
Found at: doi:10.1371/journal.ppat.1000128.s003 (1.27 MB TIF)
Table S1 Structural similarity of poxvirus, herpesvirus and
cellular Bcl-2–like proteins. The PDB ID of each structure is
shown (with chain or member of NMR ensemble used for the
analysis shown in parentheses). C
a rmsds and number of
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evolutionary distances are shown below.
Found at: doi:10.1371/journal.ppat.1000128.s004 (0.13 MB
DOC)
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